The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Sarepta Therapeutics, Inc.

  • SRPT
  • NASDAQ
  • Consumer Products
  • Latest 24.40
  • Currency US$
  • Change 0.17
  • Percent Change 0.702 %
  • Volume 1,001,565
  • Thu Apr 17, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
  • Open 24.01
  • Previous Close 24.23
  • High 24.74
  • Low 23.42
  • Bidx0 0.0000
  • Askx0 0.0000
  • 52-week High10/07 55.61
  • 52-week Low11/13 12.12
  • Beta 0.403
  • Market Cap 916.95M
  • EPS -3.39
  • P/E
  • Forward P/E
  • PEG
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $14,220,000
  • Earnings $-111,980,000
  • Return on Equity n/a

Cash Flow

  • Cash Flow --
  • Cash $256,960,000
  • Current Ratio 7.53

12 months ended Dec 31, 2013.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $291,560,000
  • Liabilities $44,370,000
  • Liabilities-to-Equity Ratio 0.18

Price Ratios

  • Price to Sales 64.48
  • Price to Book 3.71
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Feb 27 $-0.70 May 8 $-0.78
Surprises Feb 27 24.29% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Apr 17, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma, Inc., is headquartered in Bothell, Washington.

Related Securities
Symbol Type Latest % Chg

Officers

  • William Goolsbee Chairman of the Board
  • Christopher Garabedian President; Chief Executive Off
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

215 FIRST STREET SUITE 7
CAMBRIDGE, MA
02142

Phone: (857)-242-3700
Fax: (425)-3545038

ecox@sarepta.com
www.sareptatherapeutics.com

Ideas & Discussion

Live Discussion of SRPT on StockTwits